Achieved key clinical milestones with positive ADAPT-PO Phase 3 data and SPR720 IND acceptance
Conference call and live webcast at 4:30 p.m. EST today
“We made significant clinical progress in the third quarter with the announcement that the ADAPT-PO Phase 3 trial met its primary endpoint,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “The ADAPT-PO trial was a rigorous test for tebipenem HBr, having been the first trial ever to test an all oral regimen against an all IV regimen for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). We are excited by the positive results seen in the ADAPT-PO trial, which were presented at IDWeek 2020. These results highlight the potential benefit oral tebipenem HBr could offer to patients with cUTI and AP, who are in need of a new treatment option that may allow them to avoid unnecessary hospitalizations.”
Clinical Highlights and Upcoming Milestones
Spero is committed to advancing its clinical programs while protecting the safety and well-being of patients, physicians and their staff. Spero is monitoring the impact of the COVID-19 pandemic on it business and clinical programs. Spero does not foresee material impacts of the COVID-19 pandemic on its clinical plans at this time and is maintaining its current milestone guidance for its pipeline products.
Spero’s lead product candidate, tebipenem HBr, has the potential to be the first oral carbapenem antibiotic, if approved, to treat cUTI, including AP. In
Data presented at IDWeek 2020 expanded on the topline data, and demonstrated that both the clinical cure and microbiological eradication rates were comparable between treatment groups at the end of treatment (EOT), TOC and at the late follow-up (LFU) visits. Specifically, clinical cure rates, which are the key determinant in routine clinical management of cUTI/AP patients, were >93% in both treatment groups at TOC. The high clinical cure rates at TOC were sustained through LFU (88.6% and 90% for tebipenem HBr and ertapenem, respectively), demonstrating a durable clinical response in patients with cUTI and AP. Favorable microbiological response rates at TOC were likewise comparable between treatment groups and were similarly sustained up to LFU in both treatment groups (57.2% and 58.2% for tebipenem HBr and ertapenem, respectively). There were no statistically significant differences between treatment groups in overall response rates across key subgroups of interest, including those determined by age, baseline diagnosis, and presence of bacteremia at baseline. Per pathogen microbiological response rates were generally balanced across treatment groups for the predominant uropathogens. Comparative safety and tolerability data from 1,372 hospitalized adult patients enrolled in the study were similar between the tebipenem HBr and ertapenem treatment groups. Twenty six percent of subjects in both treatment groups experienced one or more treatment-emergent adverse events. The most commonly reported treatment emergent adverse events in both treatment groups were diarrhea (5.7% and 4.4% for tebipenem HBr and ertapenem, respectively) and headache (3.8% in both treatment groups).
Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the U.S. Food and Drug Administration (FDA) for the treatment of cUTI. Spero intends to make an NDA submission to the FDA for tebipenem HBr in the second quarter of 2021.
SPR720 is an orally administered antimicrobial agent being developed by Spero for the treatment of non-tuberculous mycobacterial (NTM) disease, a rare orphan disease, as well as other infections, including Mycobacterium tuberculosis. Spero announced positive topline data from its Phase 1 clinical trial of SPR720 in healthy volunteers in December 2019. Both the Phase 1 trial and pharmacokinetic/pharmacodynamic (PK/PD) data recently presented at IDWeek 2020 indicated that predicted therapeutic exposures could be attained with a 500 – 1,000 mg once daily oral dose. Spero received acceptance of its IND application for SPR720 in
Spero’s Phase 2a clinical trial will be a multi-center, partially blinded, placebo-controlled proof-of-concept clinical trial of SPR720 that will enroll approximately 90 treatment inexperienced patients with NTM pulmonary disease due to Mycobacterium avium complex (MAC). Patients will be randomized to receive either 500 mg or 1,000 mg of oral SPR720, placebo or standard of care consisting of a macrolide and ethambutol, plus the option of adding a rifamycin. The objectives of the trial are to evaluate plasma pharmacokinetics, safety, tolerability, and microbiological response of SPR720 compared with placebo and standard of care over 28 days of treatment.
SPR206 is an IV-administered product candidate being developed as an innovative option to treat multi-drug resistant (MDR) Gram-negative bacterial infections. In January 2020, Spero reported positive Phase 1 clinical trial results for SPR206 in healthy volunteers. Under its agreement with Everest Medicines, Spero expects to receive a
Third Quarter 2020 Financial Results
Spero reported a net loss for the third quarter ended September 30, 2020 of $18.9 million or $0.86 per common share, compared to a net loss of $17.7 million or $0.95 per common share reported for the same period in 2019.
Total revenue for the third quarter of 2020 was $4.0 million, compared with revenues of $4.6 million in the third quarter of 2019, the decrease due primarily to lower reimbursement in the third quarter of 2020 under Spero’s contract with the Biomedical Advanced Research and Development Authority (BARDA) for qualified tebipenem HBr expenses.
Research and development expenses for the third quarter of 2020 were $17.7 million, compared with $18.5 million of research and development expenses for the same period of 2019. This year-over-year decrease was due to lower expenses in the tebipenem HBr program following the completion of significant activities in the ADAPT-PO Phase 3 clinical trial. Spero expects to continue to incur expenses related to tebipenem HBr as it finalizes activities in the Phase 3 clinical trial and advances a potential NDA filing for tebipenem HBr.
General and administrative expenses for the third quarter of 2020 of $5.3 million were higher than the $4.1 million reported in the same period of 2019, primarily due to increased headcount and professional fees to support precommercial activities and growth of the business. Spero continues to expect general and administrative expenses to increase to support tebipenem HBr through potential approval, as well as to support Spero’s other product candidates.
As of September 30, 2020, Spero had cash and cash equivalents of $127.2 million, inclusive of
Upcoming Investor and Clinical Presentations
- Corporate presentation at the Stifel Virtual Healthcare Conference on
November 18, 2020at 10:00 AM ET
- Corporate presentation at the
Evercore ISI HealthCONx Virtual Conferenceon December 3, 2020at 8:25 AM ET
Conference Call and Webcast
Spero will host a conference call and webcast today at 4:30 p.m. EDT. To access the call, please dial (800) 239-9838 (domestic) or (323) 794-2551 (international) and refer to conference ID 8427958. The conference call will also be webcast live and a link to the webcast can be accessed here and also on Spero Therapeutics' website at www.sperotherapeutics.com in the "Investors and Media" section under "Events and Presentations." An archived webcast will be available on Spero's website for 30 days following the presentation.
About Spero Therapeutics
Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.
Spero is also advancing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.
Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.
For more information, visit https://sperotherapeutics.com.
This press release may contain forward-looking statements. These statements include, but are not limited to, statements about the initiation, timing and submission to the FDA of a NDA for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future commercialization, the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr generally; expected broad access across payer channels for tebipenem HBr; the expected pricing of tebipenem HBr and the anticipated shift from IV to oral administration; the design, initiation, timing, progress and results of Spero’s preclinical studies and clinical trials and its research and development programs, including the commencement of Spero’s planned Phase 2a clinical trial of SPR720 and the commencement of Spero’s planned Phase 1 bronchoalveolar lavage (BAL) clinical trial assessing the penetration of SPR206 into the pulmonary compartment and its renal impairment study of SPR206; management’s assessment of the results of such preclinical studies and clinical trials; the direct and indirect impact of the pandemic caused by an outbreak of a new strain of coronavirus on Spero’s business and operations, including manufacturing, research and development costs, clinical trials, regulatory processes and employee expenses; and Spero’s cash forecast and anticipated expenses, anticipated payments under Spero’s agreement with Everest Medicines, potential payments under Spero’s agreement with BARDA, the sufficiency of its cash resources and the availability of additional non-dilutive funding from governmental agencies beyond any initially funded awards. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Spero’s ability to timely complete related Phase 1 trials for its planned NDA submission for tebipenem HBr, taking into account the possible effects of the COVID-19 pandemic; Spero’s need for additional funding; the lengthy, expensive, and uncertain process of clinical drug development; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero’s reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; the ability to develop and commercialize Spero’s product candidates, if approved; the potential impact of the COVID-19 pandemic; Spero’s ability to retain key personnel and to manage its growth; whether Spero will satisfy all of the pre-conditions to receipt of the development milestone payment under its agreement with Everest Medicines; whether BARDA elects to exercise its second option under Spero’s agreement with BARDA; whether Spero’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the “Risk Factors” set forth in filings that Spero periodically makes with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Spero’s views as of the date of this press release. Spero anticipates that subsequent events and developments will cause its views to change. However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release.
Spero Investor and Media Contact:
Vice President, Investor Relations
|Condensed Consolidated Statements of Operations|
|(Unaudited, Amounts in Thousands, Except Share and Per Share Data)|
|Three Months Ended
||Nine Months Ended
|Research and development||17,706||18,495||53,798||40,047|
|General and administrative||5,309||4,133||13,942||11,803|
|Total operating expenses||23,015||22,628||67,740||51,850|
|Loss from operations||(19,020||)||(17,985||)||(60,317||)||(37,333||)|
|Other income (expense)||84||268||622||1,394|
|Net loss attributable to common shareholders of
|Net loss per share attributable to common shareholders per share, basic and diluted||$||(0.86||)||$||(0.95||)||$||(2.91||)||$||(2.01||)|
|Weighted average shares outstanding, basic and diluted:||21,933,922||18,659,079||20,712,720||17,859,829|
|Condensed Consolidated Balance Sheet Data|
|(Unaudited, Amounts in thousands)|
|Cash, cash equivalents and marketable securities||$||127,244||$||82,045|
|Total stockholder's equity||132,789||74,574|
|Total liabilities and stockholders' equity||$||157,040||$||106,103|
Source: Spero Therapeutics, Inc.